866587-81-7

Usage

Uses

Used in Pharmaceutical Synthesis:
[3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol is used as a building block for the development of new pharmaceuticals due to its unique chemical structure and properties. Its incorporation into various drug molecules can potentially enhance their efficacy, selectivity, and pharmacokinetic profiles.
Used in Chemical Research:
In the field of chemical research, [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol serves as an essential compound for exploring new reaction pathways and understanding the reactivity of pyrazole-based molecules. Its study can lead to the discovery of innovative synthetic methods and the creation of novel chemical entities with diverse applications.
Used in Organic Compounds Synthesis:
[3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol is also used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the development of new materials with specific properties, such as improved stability, reactivity, or selectivity, which can be beneficial in various industrial applications.
Used in the Chemical Industry:
Within the chemical industry, [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol is utilized as a versatile building block for the creation of a wide range of products, from specialty chemicals to advanced materials. Its adaptability and reactivity make it a valuable asset in the development of innovative and high-performance products.
Safety and Handling:
It is crucial to handle [3-(1,3,5-trimethyl-1H-pyrazol-4-yl)phenyl]methanol with care, as it may pose health and environmental hazards if not properly managed. Appropriate safety measures, including the use of personal protective equipment and adherence to established safety protocols, should be taken to minimize risks associated with its use.

Upstream product

• 866587-80-6 3-(1,3,5-trimethylpyrazol-4-yl)benzaldehyde 

Relevant academic research and scientific papers

Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold

The free fatty acid receptor 1 (FFA1) is being considered to be a novel anti-diabetic target based on its role in amplifying insulin secretion. We have previously identified several series of FFA1 agonists with different heterocyclic scaffolds. Herein, we describe the structural exploration of other heterocyclic scaffolds directed by drug-like physicochemical properties. Further structure-based design and chiral resolution provided the most potent compound 11 (EC50 = 7.9 nM), which exhibited improved lipophilicity (LogD7.4: 1.93), ligand efficiency (LE = 0.32) and ligand lipophilicity efficiency (LLE = 6.2). Moreover, compound 11 revealed an even better pharmacokinetic property than that of TAK-875 in terms of plasma clearance, maximum concentration, and plasma exposure. Although robust agonistic activity and PK profiles for compound 11, the glucose-lowering effects in vivo is not ideal, and the exact reason for in vitro/in vivo difference was worthy for further exploration.

ALKOXYPHENYLPROPANOIC ACID DERIVATIVES

The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents for the prophylaxis or treatment of GPR40 receptor-related pathology or diseases in mammals.